Results 151 to 160 of about 7,987 (192)

A Bayesian network meta-analysis: evaluating the efficacy and safety of targeted therapies in metastatic or advanced radioiodine-refractory differentiated thyroid cancer. [PDF]

Front Oncol
Wang P, Li L, Liu Y, Shi Y, Zhang X, Wu J.   +5 more
europepmc   +1 more source

Case Report: Synchronous cutaneous and pineal metastases from gastric adenocarcinoma-inter-lesion biomarker heterogeneity and multi-line targeted therapy. [PDF]

Front Oncol
Shen Q, Zhang W, Chen Y.
europepmc   +1 more source

Current and future therapies for triple-negative breast cancer. [PDF]

J Hematol Oncol
Wang ZX, Liu XY, Wu YX, Xiao YL, Ge LP, Wu SY, Jiang YZ, Shao ZM.   +7 more
europepmc   +1 more source

Bioengineered Anti-PD-L1 Functionalized Nanoplatform for Targeted Delivery and Tumor Immune Reprogramming Against Colorectal Cancer. [PDF]

Biomater Res
Liu M, Ma X, Zhou R, Yang X, Zhou Y, Ma B, Su C, Duan X.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Apatinib

Reactions Weekly, 2017
  +19 more sources

The safety of apatinib for the treatment of gastric cancer

Expert Opinion on Drug Safety, 2018
Apatinib is an orally administered small-molecule vascular endothelial growth factor receptor 2 inhibitor. It has been approved and indicated for advanced gastric cancer after the failure of two or more lines of systemic therapy in China. Areas covered: This review summarizes the mechanisms, clinical applications and safety evaluations of apatinib ...
Jin Li, Li Song, Lin Zhao
exaly   +3 more sources